Sanofi Stock Euronext Paris
Stocks
SANNV
FR001400M6Z3
Pharmaceuticals
OTC Markets Traded| Market Cap | 86.19B 96.96B 79.89B 72.68B 137B 9,202B 139B 960B 376B 4,802B 364B 356B 15,309B | P/E 2026 * |
11.7x | P/E 2027 * | 10.2x |
|---|---|---|---|---|---|
| Enterprise Value | 97.53B 110B 90.39B 82.24B 155B 10,413B 158B 1,087B 426B 5,434B 412B 403B 17,322B | EV / Sales 2026 * |
2.06x | EV / Sales 2027 * | 1.87x |
| Free-Float |
88.34% | Yield 2026 * |
5.92% | Yield 2027 * | 6.26% |
Last Transcript: Sanofi
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/05/2026 | |
| Director of Finance/CFO | 64 | 01/04/2024 | |
Paulo Fontoura
CTO | Chief Tech/Sci/R&D Officer | - | 01/09/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 30/04/2019 | |
Rachel Duan
BRD | Director/Board Member | 56 | 28/04/2020 |
Lise Kingo
BRD | Director/Board Member | 65 | 28/04/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 96.96B | |
| +0.43% | +6.59% | +56.57% | +106.64% | 1,120B | |
| +0.90% | -2.25% | +32.26% | +63.73% | 616B | |
| +0.71% | +3.24% | +24.33% | +91.33% | 504B | |
| -0.13% | +5.98% | +33.66% | +50.18% | 367B | |
| +0.52% | +0.24% | +72.13% | +40.11% | 360B | |
| -0.95% | +4.70% | +19.65% | +42.71% | 288B | |
| -1.98% | +3.73% | -0.89% | +10.43% | 258B | |
| -0.35% | +4.25% | +44.74% | +52.06% | 234B | |
| -0.75% | +3.32% | +27.18% | +94.07% | 194B | |
| Average | -0.16% | +3.61% | +34.40% | +61.25% | 437.88B | |
| Weighted average by Cap. | +0.13% | +3.83% | +39.34% | +71.82% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.4B 53.32B 43.93B 39.97B 75.43B 5,061B 76.63B 528B 207B 2,641B 200B 196B 8,419B | 50.49B 56.8B 46.79B 42.57B 80.34B 5,390B 81.63B 562B 221B 2,813B 213B 209B 8,967B |
| Net income | 7.46B 8.39B 6.91B 6.29B 11.87B 797B 12.06B 83.11B 32.59B 416B 31.5B 30.83B 1,325B | 8.72B 9.81B 8.08B 7.35B 13.87B 931B 14.09B 97.12B 38.08B 486B 36.81B 36.02B 1,548B |
| Net Debt | 11.34B 12.75B 10.51B 9.56B 18.04B 1,210B 18.33B 126B 49.52B 632B 47.87B 46.85B 2,014B | 8B 9B 7.42B 6.75B 12.74B 855B 12.94B 89.18B 34.97B 446B 33.8B 33.08B 1,422B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
